AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01080495 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TEE (transesophageal echocardiography)
Description: a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
Study NCT04409353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study NCT04409353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study NCT04409353 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PICO G2 4k
Description: Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
Study NCT04417946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP messages
Description: The peer leaders and the study staff will post PrEP related health messages
Study NCT04417946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heath messages
Description: The peer leaders and study staff will post general health messages that are not related to sexual health
Study NCT00923533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
Study NCT00923533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
Study NCT01193920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 20/20/20 μg
Description: Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
Study NCT01193920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Subjects received two injection of saline solution.
Study NCT01193920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg
Description: Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
Study NCT01193920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg
Description: Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
Study NCT01193920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus Trivalent Vaccine - 5/5/5 μg
Description: Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
Study NCT01193920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Subjects received one injection of saline solution.
Study NCT02230553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT02230553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Study NCT04341766 — intervention group
Intervention type: OTHER
Intervention: No special intervention
Description: No special intervention : Ultrasound data will be collected
Study NCT02924142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OT Cap attachment
Description: The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
Study NCT00607022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant
Description: Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
Study NCT02727465 — intervention group
Intervention type: OTHER
Intervention: Meningitis cases
Description: None - blood draw only
Study NCT03244735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atkins diet
Description: A nutritional regimen characterized by high fat low carbohydrate intake.
Study NCT00969410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299
Description: AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
Study NCT00227890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI/CBT
Study NCT00227890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT/TU
Study NCT02767128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Study NCT02767128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fer-In-Sol
Study NCT02767128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shohl's solution
Study NCT01795027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: 6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
Study NCT01795027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 single
Description: 16 courses S-1 single after d D2 resection
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
Study NCT01079130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Salmeterol
Description: Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
Study NCT00390910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses
Study NCT00390910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses
Study NCT04596696 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavac
Description: Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
Study NCT01620112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high Clonidine concentration
Description: Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
Study NCT01620112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low clonidine concentration
Description: Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
Study NCT01620112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
Study NCT01620112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 40 ml
Description: Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
Study NCT02440230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFS + Anastrozole
Description: Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd.
Study NCT02440230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFS + Exemestane
Description: Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
Study NCT03163485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialytrode
Description: Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
Study NCT03163485 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard treatment
Description: Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
Study NCT05134051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)
Description: IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
Study NCT02960841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracavitary Manual Lymphatic Drainage
Study NCT02960841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Study NCT02849288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
Description: Automated Insulin Delivery System
Study NCT04740554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group with Deflazacort
Description: Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
Study NCT04740554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group with Prednisone/Predisolone
Description: Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
Study NCT04740554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Duchenne Muscular Dystrophy group without Corticosteroids therapy
Description: Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
Study NCT04740554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control Group Typically Developing
Description: Control group with tipical development.
Study NCT00675805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infusomat filter (Codan Duofilter-Set V86-P)
Description: An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
Study NCT00675805 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IVIG application without filter (Placebo)
Description: Application Intravenous immunoglobulins without filter (Placebo)
Study NCT01377753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualase Thermal Therapy System
Description: Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
Study NCT01668511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: Injection
Study NCT01668511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Injection
Study NCT01829399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Epinephrine
Description: 10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
Study NCT01829399 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Study NCT01377051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol maleate
Description: Dry powered, 300 mcg, only one inhalation with 24 hours duration
Study NCT01377051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powered, same to study drug, only one inhalation
Study NCT00879112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07811
Description: Oral
Study NCT00879112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02132546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Study NCT00330265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KC-002
Description: Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
Study NCT00330265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Wound Therapy
Description: Normal Saline Dressings
Study NCT00763737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion
Description: prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
Study NCT00346268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine, Parecoxib
Description: Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
Study NCT00346268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine, Placebo
Description: Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Over-encapsulated zolpidem tablet at a strength of 10 mg
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Placebo capsules matching ACT-541468 capsules
Study NCT02839200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Placebo capsules matching over-encapsulated zolpidem
Study NCT02008799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow stem cell injection
Description: Injection should be in testis and testicular artery
Study NCT01198496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
Description: \<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
Study NCT04466319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking Chair
Description: Patients in the experimental group were sat rocking chair three times a day in a rocking wooden chair in addition to their postoperative routine care by their nurses. After providing the rocking chair to the patients' room, the researcher gave the data collection form to be filled by the patient himself. It was the researcher's supervision that the patient sat in the rocking chair for the first time. The rocking chair movement continued to intervene until the patient released gas. After emitting gas, he continued to swing in the rocking chair until he made his first stools. The patient was visited every day until he was discharged. No special clothing or materials were required for the patients to sit in the rocking chair.
Study NCT02643212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study NCT02643212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03873142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting
Description: The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
Study NCT02417402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
Study NCT02417402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trained
Description: The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
Study NCT00235547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: timing of initiation of transdermal patch after an abortion
Description: the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
Study NCT01924728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic stimulation
Description: 50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
Study NCT01924728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham magnetic stimulation
Description: 50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
Study NCT02359877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-054
Study NCT02359877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif
Study NCT02359877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex